ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2026
Pinggan Yuyin Qingre formula ameliorates meibomian gland dysfunction through the interleukin-17/nuclear factor kappa B pathway based on network pharmacology and experimental validation.
Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo investigate the pharmacological effects and underlying mechanisms of Pinggan Yuyin Qingre formula (, PGYYQR) in the treatment of meibomian gland dysfunction (MGD) through network pharmacology and
methodsA mouse model of MGD was induced using the stearoyl-coenzyme a desaturase 1 inhibitor, followed by PGYYQR treatment for 2 weeks. MGD sign scoring, hematoxylin and eosin (HE) staining, oil red o (ORO) staining, and serum inflammatory cytokine analysis were conducted to assess the effects of PGYYQR on meibomian gland (MG) function, histopathology, and associated inflammation. Network pharmacology was employed to identify the active compounds and potential targets of PGYYQR. Molecular mechanisms were further investigated using Western blotting, reverse transcription quantitative real-time polymerase chain reaction, and reactive oxygen species (ROS) assays.
resultsPGYYQR treatment significantly reduced the scores of MG orifice obstruction and meibum quality in MGD mice. HE and ORO staining further demonstrated that PGYYQR ameliorated glandular damage and lipid dysfunction. Enzyme-linked immunosorbent assay results revealed that PGYYQR markedly decreased the serum levels of key inflammatory cytokines, including interleukin (IL)-1β, IL-6, and tumor necrosis factor-α. Network pharmacology identified 162 active compounds and 598 target genes in PGYYQR. Among these, IL-6, IL-1β, matrix metalloproteinase-9, and C-X-C motif chemokine ligand 8 were recognized as core targets related to MGD and were mainly enriched in the IL-17/ nuclear factor kappa B (NF-κB) signaling pathway. Further molecular analyses confirmed that PGYYQR significantly inhibited the IL-17/NF-κB axis by downregulating IL-17 expression and reducing phos-phorylated NF-κB p65 levels at both the protein and mRNA levels in MG tissues. PGYYQR also effectively reduced ROS levels in the conjunctival tissues of MGD mice.
conclusionPGYYQR effectively improves MG function and preserves local tissue morphology in MGD model mice, primarily by suppressing the inflammatory response through coordinated modulation of the IL-17/NF-κB signaling pathway and oxidative stress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.